Careers
Contact
India flag iconIndiaUSA flag iconUSAGreat Britain flag iconUKSouth Africa flag iconSouth AfricaAustralia flag iconAustraliaPhilippines flag iconPhilippinesGermany flag iconGermanyNetherlands flag iconNetherlandsMexico flag iconMexicoBrazil flag iconBrazilCanada flag iconCanadaSwitzerland flag iconSwitzerland
Decorative petal
Product Finder
Product Finder
Press Releases

Lupin receives U.S. FDA approval for Fosaprepitant for Injection

Mumbai, Baltimore: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Fosaprepitant for Injection, 150 mg Single-Dose Vial, from the United States Food and Drug Administration    (U.S. FDA).

Lupin’s Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic version of Emend® for Injection, 150 mg Single-Dose Vial, of Merck Sharp & Dohme Corp. (Merck). It is indicated for adults in combination with other antiemetic agents, for the prevention of:

  • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
  • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).
Fosaprepitant for Injection, 150 mg Single-Dose Vial, had annual sales of approximately USD 285 million in the US (IQVIA MAT June 2019).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company by revenues (31st Mar 2019, Bloomberg LTM) respectively. The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Jun 2019); 3rd largest Indian pharmaceutical company by global revenues (31st Mar 2019, Bloomberg LTM); 5th largest generic pharmaceutical player in Japan and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT Jun 2019).

For the financial year ended 31st March, 2019, Lupin’s Consolidated sales and Net profits were at Rs. 163,694 million (USD 2.34 billion) and Rs. 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055. 

For further information or queries please contact –

Pooja Thakran VP – Corporate Communications Email: poojathakran@lupin.com Ph: +91-22-66402531 / 8291013225

Or

Arvind Bothra Head – Investor Relations Email: arvindbothra@lupin.com Ph: +91-22-66408237

*Safe Harbor Statement

Emend® is the registered trademark of Merck Sharp & Dohme Corp

Product Finder